You might also like
InfuSystem Holdings, Inc. is a leading national health care service provider that facilitates outpatient care for durable medical equipment manufacturers and health care providers. The company operates under a two-platform model, offering a range of services and products that support clinic-to-home healthcare solutions. InfuSystem sells and rents ambulatory and large-volume infusion pumps, along with providing biomedical services and repair.
-
Patient Services - Provides a last-mile solution for clinic-to-home healthcare, focusing on treatments involving complex durable medical equipment and services.
- Oncology - Offers services and equipment for cancer treatment.
- Pain Management - Supplies equipment and services for managing patient pain.
- Wound Therapy - Provides solutions for wound care and healing.
- Lymphedema - Offers services for managing lymphedema conditions.
-
Device Solutions - Supports the Patient Services platform with direct payer rentals, pump and consumable sales, and biomedical services and repair.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Barry Steele Executive | Chief Financial Officer (CFO) | None | Joined INFU in March 2020. CPA with prior CFO roles at Horizon Global Corporation and Gentherm. | |
Carrie Lachance Executive | President and Chief Operating Officer (COO) | None | Joined INFU in 2010; promoted to President and COO in March 2021. Background as a registered nurse and certified infusion nurse with over 25 years of healthcare experience. | |
Richard DiIorio Executive | Chief Executive Officer (CEO) | Board Member at Dignitana AB (NASDAQ: DIZTF) | Joined INFU in 2004; became CEO in November 2017. Extensive experience in healthcare sales, customer service, and market growth strategies. | View Report → |
Beverly A. Huss Board | Director Nominee | Director at Accuray Incorporated, Iridex Inc., and Vicarious Surgical Inc. | Extensive experience in the medical device industry, including CEO roles and board leadership. | |
Gregg Lehman Board | Director | CEO of EB Employee Solutions, LLC; President of Lehman Ventures LLC | Former INFU Chairman and Vice Chairman. Over 40 years of senior executive experience in public and private companies. | |
Kenneth Eichenbaum Board | Director | Practicing Anesthesiologist at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital | Board-certified anesthesiologist with expertise in infusion pumps and med-tech evaluation. | |
Paul Gendron Board | Director | Member of the Accounting Advisory Council at the University of Texas at Austin | Former PwC audit partner with 30+ years of public accounting experience. Expertise in governance, risk management, and financial reporting. | |
Ralph Boyd Board | Director | President & CEO of SOME, Inc.; Director at Sandy Spring Bancorp (NASDAQ: SASR) | Governance and strategy expert with experience in nonprofit leadership and corporate boards. | |
Ronald Hundzinski Board | Director | Chairman of the Board at Gentherm, Inc. | Former CFO of TI Fluid Systems and BorgWarner. Audit committee financial expert with significant public company experience. | |
Scott Shuda Board | Chairman of the Board | Chairman of Iridex Corporation (NASDAQ: IRIX); Managing Director of Meridian OHC Partners, LP and BlueLine Partners, LLC; Founder of Breakout Investors; Managing Director of TSV Investment Partners, LLC | Co-founder of investment firms focusing on healthcare and technology. Over 25 years of experience in law, technology, and corporate governance. |
-
You mentioned that it's too early to know how quickly the opportunity with Chemo Mouthpiece will develop and its ultimate size; given this uncertainty, how are you planning to manage the risks associated with this product launch, and what milestones should we expect to gauge its progress?
-
Your net capital expenditures were $2.9 million during the third quarter, higher than $300,000 in the same quarter last year, due to purchases for oncology and wound care; with expectations to moderate CapEx, can you elaborate on your capital allocation strategy and how it aligns with your growth plans in these segments?
-
While your adjusted EBITDA margin reached 22.3% this quarter, surpassing last year's 17.8%, you mentioned margins are typically lower in the first quarter; what steps are you taking to sustain or improve margins throughout the year, and what are the main factors that could impact this performance?
-
With several new partnerships and initiatives, such as those with Smith & Nephew, Sanara MedTech, and Dignitana, how do you prioritize these opportunities within your overall growth strategy, and what measures are in place to ensure these ventures contribute meaningfully to your revenue and profitability?
-
Given that the initial regulations under the NOPAIN Act do not favor your current pain management offerings and you've mentioned that pain management is moving down your list of priorities, what is your long-term vision for this segment, and how will you address the challenges it faces?
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
OB Healthcare | 2021 | Completed on April 18, 2021, InfuSystem acquired OB Healthcare for an approximate total consideration of $6.3 million (including a $6.1 million cash payment, working capital adjustments, and $0.8 million in contingent consideration payable by December 31, 2021). The deal brought key biomedical service capabilities—such as on-site repair, preventative maintenance, and device physical inventory management—and expanded InfuSystem’s Durable Medical Equipment Services segment, complementing its existing remote repair offerings. |
FilAMed | 2021 | Completed on January 31, 2021, InfuSystem acquired FilAMed for a total of $1.4 million in cash. This acquisition, aimed at strengthening its Durable Medical Equipment Services segment, provided strategic expansion into biomedical recertification, maintenance, and repair services for the acute care market, with detailed allocation of purchase price across intangibles, goodwill, and operational assets. |
Recent developments and announcements about INFU.
Earnings
New Earnings (Q4 2024)
·Mar 4, 2025, 6:17 PMView full earnings summary →INFU aims for 2025 EBITDA margins above 20% on growth in Wound Care & Biomed. ChemoMouthpiece could tap a $500-$600M market in oral mucositis, filling an unmet need. Oncology remains modest at 3-6%, limiting revenue upside. ChemoMouthpiece success is key.
8-K Filings
8-K Filing
·Feb 25, 2025, 12:11 PMFinancial ExhibitsView full 8-K filing →InfuSystem will release preliminary Q4 and full-year 2024 financial results on March 4, 2025 before market open. A conference call is set for 9:00 AM ET; dial-in and webcast details are in the press release.